Health-care shares were flat to higher in pre-market trade
In health-care stocks news, Auspex Pharmaceuticals (
), a biopharmaceutical company, has completed the enrollment of 90
patients in its Phase 3 registration clinical trial of SD-809 for
the potential treatment of chorea associated with Huntington's
The company said it expects to announce the topline data from
this study in the fourth quarter of 2014.
Biopharmaceutical company Achillion Pharmaceuticals (
) was upgraded by analysts at Deutsche Bank to a buy rating from a
The firm also nearly tripled its price target on the stock to
$17 from $6 a share, which represents a potential upside of 84%
from its Friday close.
Shares of ACHN surged more than 7% to $9.90 in Monday's
pre-market session, and were closing in on the top of their 52-week
trading range of $2.26 - $9.94.
And, Liberator Medical Holdings (
) said Q3 net sales increased by $1,087,000, or 6.2%, to
$18,578,000, compared with net sales of $17,491,000 for Q3
Meanwhile, income from operations decreased by $240,000, or
7.2%, to $3,116,000. Earnings per share were $0.04, on par with a
year prior. Analyst estimates were not available
Copyright (C) 2014 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.